Alexion Pharmaceuticals (ALXN) Strengthens on FDA Nod

Alexion Pharmaceuticals, Inc. ALXN shares gained 1.6% to $169.36, on word that the U.S. Food and Drug Administration (FDA) has approved Strensiq™ (asfotase alfa) for the treatment of patients with perinatal-, infantile- and juvenile-onset hypophosphatasia. Share volume was 1.4 million, compared to an all-day average of 1.8 million